No matches
Dermatology

Confidence Across the Spectrum: Addressing the Heterogeneity of CSU

This infographic explores the heterogeneity of chronic spontaneous urticaria (CSU) across patient subpopulations and highlights differences in demographic and clinical characteristics that may impact disease burden and management.

Related resources

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Unmet Needs in Bullous Pemphigoid

Unmet Needs in Bullous Pemphigoid

expert video
Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid

Bullous Pemphigoid (BP) Pathophysiology Infographic

Infographic
CSU Burden Related to Chronicity and Patient Journey

CSU Burden Related to Chronicity and Patient Journey

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

expert video
The Importance of Disease Control in Reducing CSU Patient Burden

The Importance of Disease Control in Reducing CSU Patient Burden

expert video
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

expert video
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

expert video
Bullous Pemphigoid Mechanism of Disease Video

Bullous Pemphigoid Mechanism of Disease Video

videoanimation
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

expert video
Importance of Early Diagnosis in Bullous Pemphigoid

Importance of Early Diagnosis in Bullous Pemphigoid

expert video
Risk of Mortality and Infections in Bullous Pemphigoid

Risk of Mortality and Infections in Bullous Pemphigoid

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
Targeted Approaches to Holistic Management of PN

Targeted Approaches to Holistic Management of PN

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

expert video
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

expert video
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg

Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg

expert video
On the Surface: Restoring the Skin Barrier in Patients With AD

On the Surface: Restoring the Skin Barrier in Patients With AD

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

expert video
Beyond Age: Unraveling the Mortality Risk in Bullous Pemphigoid

Beyond Age: Unraveling the Mortality Risk in Bullous Pemphigoid

expert video
The Multifactorial Burdens of Bullous Pemphigoid

The Multifactorial Burdens of Bullous Pemphigoid

expert video
The Impacts of Delayed Diagnosis and Treatment in Bullous Pemphigoid

The Impacts of Delayed Diagnosis and Treatment in Bullous Pemphigoid

expert video
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

expert video
On the Surface: Restoring the Skin Barrier in Patients with AD

On the Surface: Restoring the Skin Barrier in Patients with AD

expert video
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

expert video
Bullous Pemphigoid Is a Challenging Disease to Manage

Bullous Pemphigoid Is a Challenging Disease to Manage

expert video
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis

Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases

Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases

expert video
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases

Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases

expert video
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention

Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention

expert video
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology

Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology

expert video
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

expert video
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment

Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment

expert video
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

expert video
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

expert video
The Patient's Path: Unraveling the Diagnosis and Burden of Bullous Pemphigoid

The Patient's Path: Unraveling the Diagnosis and Burden of Bullous Pemphigoid

videoanimation
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

expert video
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

expert video
ADVENT On Air Podcast: Unmet Needs and Current Treatment Landscape with Bullous Pemphigoid

ADVENT On Air Podcast: Unmet Needs and Current Treatment Landscape with Bullous Pemphigoid

Podcast
ADVENT On Air | Burden of Disease and Diagnosis of Bullous Pemphigoid

ADVENT On Air | Burden of Disease and Diagnosis of Bullous Pemphigoid

Podcast

Learning objectives

  • Recognize each CSU patient as a unique mosaic of demographic and clinical characteristics.
  • Understand how patient characteristics may influence disease burden and considerations for the management of CSU.
Tags
Burden of Diseaseendotypeheterogeneitypatient burden
MAT-GLB-2605666 - 1.0 - 10/2026

This website is intended for healthcare professionals practicing in Romania.

The Summary Product Characteristics of Dupilumab is available here.

Dupilumab is dispensed on medical prescription type PR.

For the request of medical information, the reporting of adverse reactions and / or quality complaints, please call the call center service 24/7, phone (+40) 021 317 31 36, or contact us by email at the following addresses: ro.medical_info@sanofi.com - Medical Department, quality.ro@sanofi.com - Quality Department, pv.ro@sanofi.com - Pharmacovigilance Department.

You may also report adverse reactions to Sanofi medicinal products to the National Agency for Medicines and Medical Devices from Romania (NAMMDR); for details on reporting side effects, visit the NAMMDR website.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: RomaniaChange country/region